318 related articles for article (PubMed ID: 26511486)
1. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
2. Persistent p21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells.
Wang Z; Lee HJ; Chai Y; Hu H; Wang L; Zhang Y; Jiang C; Lü J
Curr Cancer Drug Targets; 2010 May; 10(3):307-18. PubMed ID: 20370687
[TBL] [Abstract][Full Text] [Related]
3. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells.
Hu H; Jiang C; Li G; Lü J
Carcinogenesis; 2005 Aug; 26(8):1374-81. PubMed ID: 15845651
[TBL] [Abstract][Full Text] [Related]
4. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
5. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells.
Li GX; Hu H; Jiang C; Schuster T; Lü J
Int J Cancer; 2007 May; 120(9):2034-43. PubMed ID: 17230520
[TBL] [Abstract][Full Text] [Related]
6. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
7. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
8. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
[TBL] [Abstract][Full Text] [Related]
9. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
10. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
11. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
[TBL] [Abstract][Full Text] [Related]
15. Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia.
Sinha I; Allen JE; Pinto JT; Sinha R
Cancer Med; 2014 Apr; 3(2):252-64. PubMed ID: 24515947
[TBL] [Abstract][Full Text] [Related]
16. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
Chen Z; Carracedo A; Lin HK; Koutcher JA; Behrendt N; Egia A; Alimonti A; Carver BS; Gerald W; Teruya-Feldstein J; Loda M; Pandolfi PP
Sci Signal; 2009 Aug; 2(84):ra44. PubMed ID: 19690330
[TBL] [Abstract][Full Text] [Related]
17. Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.
Hafeez BB; Fischer JW; Singh A; Zhong W; Mustafa A; Meske L; Sheikhani MO; Verma AK
Cancer Prev Res (Phila); 2015 May; 8(5):375-86. PubMed ID: 25627799
[TBL] [Abstract][Full Text] [Related]
18. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.
Sinha I; Null K; Wolter W; Suckow MA; King T; Pinto JT; Sinha R
Int J Cancer; 2012 Mar; 130(6):1430-9. PubMed ID: 21500193
[TBL] [Abstract][Full Text] [Related]
19.
Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
[TBL] [Abstract][Full Text] [Related]
20. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling.
Wang Z; Jiang C; Ganther H; Lü J
Cancer Res; 2001 Oct; 61(19):7171-8. PubMed ID: 11585751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
